Cardiac Allograft Vasculopathy Clinical Trial
Official title:
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second
leading cause of late mortality after heart transplantation. CAV has been associated with a
variety of traditional risk factors for atherosclerosis; however, immune mediated injury from
development of de-novo donor-specific antibodies after transplantation also likely plays an
important role. Similar to the progression of traditional atherosclerosis, it is likely that
endothelial dysfunction is the precursor to the development of intimal thickening and CAV.
The investigators hypothesize that coronary allograft vasculopathy after heart
transplantation as defined by progressive neointimal hyperplasia is preceded by endothelial
dysfunction, which in turn is at least partly mediated by donor specific antibodies.
The investigators are proposing a prospective study in humans to test the above hypothesis
and further mechanistically understand how CAV progresses. In this study the investigators
will test for coronary endothelial function by infusing acetylcholine into the coronary
artery and measure intimal hyperplasia by optical coherence tomography (OCT) and compare
findings in patients with and without donor specific antibodies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02880137 -
Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
|
Phase 4 | |
| Terminated |
NCT01278745 -
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
|
Phase 2 | |
| Withdrawn |
NCT01812434 -
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
|
N/A | |
| Withdrawn |
NCT01305382 -
Noninvasive Evaluation of Cardiac Allograft Vasculopathy
|
N/A | |
| Recruiting |
NCT05826444 -
Microvascular Cardiac Allograft Vasculopathy Trial
|
||
| Suspended |
NCT05756088 -
Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
|
||
| Completed |
NCT02013037 -
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
|
Phase 3 | |
| Withdrawn |
NCT01157949 -
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
|
Phase 3 | |
| Withdrawn |
NCT01305395 -
Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
|
N/A | |
| Enrolling by invitation |
NCT06147271 -
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
|
Phase 2 | |
| Recruiting |
NCT04193306 -
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
|
Phase 4 | |
| Recruiting |
NCT02798731 -
Physiologic Assessment of Microvascular Function in Heart Transplant Patients
|
||
| Withdrawn |
NCT02777255 -
Severe CAV MRI in Heart Transplant Recipient
|
N/A | |
| Completed |
NCT05373108 -
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
|
Phase 4 | |
| Withdrawn |
NCT01424917 -
Noninvasive Predictors of Transplant Vasculopathy
|
N/A | |
| Recruiting |
NCT04770012 -
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT01078363 -
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
|
N/A | |
| Completed |
NCT03734211 -
Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
|
Phase 3 | |
| Recruiting |
NCT06089486 -
MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation
|
N/A | |
| Active, not recruiting |
NCT03386539 -
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
|
Phase 3 |